275 related articles for article (PubMed ID: 21317931)
1. The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer.
Privette Vinnedge LM; McClaine R; Wagh PK; Wikenheiser-Brokamp KA; Waltz SE; Wells SI
Oncogene; 2011 Jun; 30(24):2741-52. PubMed ID: 21317931
[TBL] [Abstract][Full Text] [Related]
2. The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers.
Privette Vinnedge LM; Benight NM; Wagh PK; Pease NA; Nashu MA; Serrano-Lopez J; Adams AK; Cancelas JA; Waltz SE; Wells SI
Oncogene; 2015 Apr; 34(18):2325-36. PubMed ID: 24954505
[TBL] [Abstract][Full Text] [Related]
3. DEK promotes the proliferation and invasion of lung cancers and indicates poor prognosis in lung adenocarcinomas.
Yang MQ; Bai LL; Lei L; Zheng YW; Wang Z; Li ZH; Liu CC; Huang WJ; Xu HT
Oncol Rep; 2020 Apr; 43(4):1338-1348. PubMed ID: 32020224
[TBL] [Abstract][Full Text] [Related]
4. Silencing DEK downregulates cervical cancer tumorigenesis and metastasis via the DEK/p-Ser9-GSK-3β/p-Tyr216-GSK-3β/β-catenin axis.
Xu X; Zou L; Yao Q; Zhang Y; Gan L; Tang L
Oncol Rep; 2017 Aug; 38(2):1035-1042. PubMed ID: 28627610
[TBL] [Abstract][Full Text] [Related]
5. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
[TBL] [Abstract][Full Text] [Related]
6. NMR-based metabolomic analysis identifies RON-DEK-β-catenin dependent metabolic pathways and a gene signature that stratifies breast cancer patient survival.
Vicente-Muñoz S; Hunt BG; Lange TE; Wells SI; Waltz SE
PLoS One; 2022; 17(9):e0274128. PubMed ID: 36067206
[TBL] [Abstract][Full Text] [Related]
7. The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer.
Privette Vinnedge LM; Ho SM; Wikenheiser-Brokamp KA; Wells SI
PLoS One; 2012; 7(10):e46985. PubMed ID: 23071688
[TBL] [Abstract][Full Text] [Related]
8. DEK promotes HPV-positive and -negative head and neck cancer cell proliferation.
Adams AK; Hallenbeck GE; Casper KA; Patil YJ; Wilson KM; Kimple RJ; Lambert PF; Witte DP; Xiao W; Gillison ML; Wikenheiser-Brokamp KA; Wise-Draper TM; Wells SI
Oncogene; 2015 Feb; 34(7):868-77. PubMed ID: 24608431
[TBL] [Abstract][Full Text] [Related]
9. Optical Redox Imaging Detects the Effects of DEK Oncogene Knockdown on the Redox State of MDA-MB-231 Breast Cancer Cells.
Wen Y; Xu HN; Privette Vinnedge L; Feng M; Li LZ
Mol Imaging Biol; 2019 Jun; 21(3):410-416. PubMed ID: 30758703
[TBL] [Abstract][Full Text] [Related]
10. Melanoma proliferation and chemoresistance controlled by the DEK oncogene.
Khodadoust MS; Verhaegen M; Kappes F; Riveiro-Falkenbach E; Cigudosa JC; Kim DS; Chinnaiyan AM; Markovitz DM; Soengas MS
Cancer Res; 2009 Aug; 69(16):6405-13. PubMed ID: 19679545
[TBL] [Abstract][Full Text] [Related]
11. Critical role of DEK and its regulation in tumorigenesis and metastasis of hepatocellular carcinoma.
Yu L; Huang X; Zhang W; Zhao H; Wu G; Lv F; Shi L; Teng Y
Oncotarget; 2016 May; 7(18):26844-55. PubMed ID: 27057626
[TBL] [Abstract][Full Text] [Related]
12. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
Al-Dhfyan A; Alhoshani A; Korashy HM
Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
[TBL] [Abstract][Full Text] [Related]
13. Exosomal DEK removes chemoradiotherapy resistance by triggering quiescence exit of breast cancer stem cells.
Yang YS; Jia XZ; Lu QY; Cai SL; Huang XT; Yang SH; Wood C; Wang YH; Zhou JJ; Chen YD; Yang JS; Yang WJ
Oncogene; 2022 Apr; 41(18):2624-2637. PubMed ID: 35351996
[TBL] [Abstract][Full Text] [Related]
14. Imaging-based study demonstrates how the DEK nanoscale distribution differentially correlates with epigenetic marks in a breast cancer model.
Pierzynska-Mach A; Cainero I; Oneto M; Ferrando-May E; Lanzanò L; Diaspro A
Sci Rep; 2023 Aug; 13(1):12749. PubMed ID: 37550322
[TBL] [Abstract][Full Text] [Related]
15. The human DEK oncogene regulates DNA damage response signaling and repair.
Kavanaugh GM; Wise-Draper TM; Morreale RJ; Morrison MA; Gole B; Schwemberger S; Tichy ED; Lu L; Babcock GF; Wells JM; Drissi R; Bissler JJ; Stambrook PJ; Andreassen PR; Wiesmüller L; Wells SI
Nucleic Acids Res; 2011 Sep; 39(17):7465-76. PubMed ID: 21653549
[TBL] [Abstract][Full Text] [Related]
16. CD36 upregulates DEK transcription and promotes cell migration and invasion via GSK-3β/β-catenin-mediated epithelial-to-mesenchymal transition in gastric cancer.
Wang J; Wen T; Li Z; Che X; Gong L; Jiao Z; Qu X; Liu Y
Aging (Albany NY); 2020 Nov; 13(2):1883-1897. PubMed ID: 33232276
[TBL] [Abstract][Full Text] [Related]
17. Control of tumorigenesis and chemoresistance by the DEK oncogene.
Riveiro-Falkenbach E; Soengas MS
Clin Cancer Res; 2010 Jun; 16(11):2932-8. PubMed ID: 20501624
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo.
Wise-Draper TM; Mintz-Cole RA; Morris TA; Simpson DS; Wikenheiser-Brokamp KA; Currier MA; Cripe TP; Grosveld GC; Wells SI
Cancer Res; 2009 Mar; 69(5):1792-9. PubMed ID: 19223548
[TBL] [Abstract][Full Text] [Related]
19. Promotion of cell proliferation by the proto-oncogene DEK enhances oral squamous cell carcinogenesis through field cancerization.
Nakashima T; Tomita H; Hirata A; Ishida K; Hisamatsu K; Hatano Y; Kanayama T; Niwa A; Noguchi K; Kato K; Miyazaki T; Tanaka T; Shibata T; Hara A
Cancer Med; 2017 Oct; 6(10):2424-2439. PubMed ID: 28834425
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of the human DEK oncogene reprograms cellular metabolism and promotes glycolysis.
Matrka MC; Watanabe M; Muraleedharan R; Lambert PF; Lane AN; Romick-Rosendale LE; Wells SI
PLoS One; 2017; 12(5):e0177952. PubMed ID: 28558019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
